Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received acceptance for its drug registration application for Mivacurium Injection from the National Medical Products Administration, targeting anesthesia induction and short-term surgical anesthesia [1] Group 1 - The drug registration application is classified as a Class 1 chemical drug [1] - The project code for the Mivacurium Injection is ET-26 [1] - The intended indications for the drug include use in anesthesia induction and short-term surgical anesthesia [1]

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received acceptance from the National Medical Products Administration for the drug registration application of Mivacurium Hydrochloride Injection, aimed at anesthesia induction and short-term surgical anesthesia [1] Group 1 - The new drug is classified as a Class 1 new drug for intravenous general anesthesia and was included in the "Major New Drug Creation" initiative in 2014 [1] - As of January 2026, the total R&D investment for this new drug is approximately 189 million yuan [1] - The projected sales for similar drugs in the domestic market in 2024 is around 4.238 billion yuan [1] Group 2 - Multiple approvals are required before the commercial production of the new drug, and the current acceptance does not have a significant impact on the company's performance at this stage [1]